Update app.py to adjust Gradio Blocks height and enhance chatbot layout by adding scaling to the chat interface. Modify example patient scenarios for improved relevance and clarity in the Clinical Trial Matching Chatbot.

app.py

@@ -373,7 +373,7 @@ if __name__ == "__main__":
         return get_clinical_trials(message)
     
     # Create optimized chatbot with simple, reliable CSS
-    with gr.Blocks(theme=gr.themes.Soft(), fill_height=True) as demo:
+    with gr.Blocks(theme=gr.themes.Soft(), fill_height=False) as demo:
         # Add simple CSS for styling with black text
         gr.HTML("""
         <style>
@@ -507,8 +507,9 @@ if __name__ == "__main__":
         gr.Markdown("## Start Matching")
         chatbot = gr.ChatInterface(
             fn=chat_function,
+            scale=1,
             examples=[
-                ["A 39-year-old Thai male presents for study screening. He received his second dose of an approved mRNA COVID-19 vaccine (Pfizer) over 4 months ago and has remained in good health since. He has no history of COVID-19 infection, confirmed by a negative SARS-CoV-2 rapid antigen test today. He denies any chronic illness, does not take any medications, and has never had an adverse reaction to vaccines. He is sexually active and reports consistent condom use with his partner. He is interested in participating in a study assessing immune response to a new booster dose."],
+                ["A 28-year-old non-pregnant female, otherwise healthy, presents to a community clinic to explore enrollment in a COVID-19 booster study. She completed her primary 2-dose Moderna series 5 months ago, has not received any other COVID vaccines since, and reports no history of vaccine-related side effects. Her most recent SARS-CoV-2 test today was negative. She reports consistent oral contraceptive use for over 6 months and denies any significant past medical history. She is willing to abstain from blood donation and complies with all study guidelines."],
                 ["A 19-year-old pregnant patient, receiving prenatal care at Johns Hopkins Hospital, is 28 weeks gestation and preparing to receive her first mRNA COVID-19 vaccine dose. She has no previous history of COVID-19 and no significant medical history. She meets eligibility criteria and is interested in contributing to research on pregnancy and vaccine-related immune responses."],
                 ["A 67-year-old male with relapsed/refractory multiple myeloma presents for enrollment into a post-trial access study. He previously participated in a Pfizer-sponsored parent study evaluating elranatamab, during which he achieved a partial response and remained clinically stable. At the time the parent trial ended, he was continuing on elranatamab with no evidence of disease progression or significant toxicity. He reports no history of psychiatric illness or lab abnormalities, and he wishes to continue treatment through this access program."]
             ]